Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

Abstract The discovery of cannabinoid receptors as the primary molecular targets of psychotropic cannabinoid Δ9‐tetrahydrocannabinol (Δ9‐THC) in late 1980s paved the way for investigations on the effects of cannabis‐based therapeutics in brain pathology. Ever since, a wealth of results obtained from studies on human tissue samples and animal models have highlighted a promising therapeutic potential of cannabinoids and endocannabinoids in a variety of neurological disorders. However, clinical success has been limited and major questions concerning endocannabinoid signaling need to be